Special Offer. Now 25% off the original price of $3500. In the nascent, but rapidly growing field of stem cell therapies, products are a long way from being commercialized. However, the market potential for stem cell therapies products is very large. This report aims to identify those technologies and opportunities in the United States with the greatest future opportunities, the opportunities to develop enabling technologies in the field, and the organizations and laboratories performing current research. In addition, a section is included that covers the legislative, political and social issues surrounding stem cell technology and research. These issues are impacting the development of the technology.
Objectives
This report is a convenient and comprehensive report on stem cells and the technologies being development. Objectives of the report include the following:
To describe research activities and potential
To outline problems involved in developing these technologies and the fairly rigorous regulatory challenges that companies will be facing when licensing these new therapies.
To provide the kind of current information and analysis the reader will need to make strategic business or investment decisions in the area of stem cell technology.
To provide in-depth information on most companies, organizations, and research facilities involved in the field.
Audience
This report is designed to be used primarily by executives, investors, venture capitalists, and business development managers and analysts involved in the pharmaceutical or biotechnology areas that may have an interest in stem cell technology. Companies and organizations seeking to identify partners with complementary technologies may also find this report valuable.
Stem cell research and the accompanying enabling technologies have virtually exploded since embryonic stem cells were first isolated in 1998. Many of the enabling and complementary technologies impacting stem cells are only now catching up to the rate of research. As such, there is a section on companies supplying the research, including those with cell lines, cell and tissue culture media, and reagents.
The report includes detailed profiles and information on:
82 companies involved in the development of stem cell therapeutics, worldwide,
57 academic organizations involved in stem cell research in the U.S.,
19 laboratories outside the U.S. with advanced research in the field,
20 detailed profiles on key companies in the industry,
32 suppliers to the Stem Cell Industry, of media, sera, and reagents specifically intended for stem cell research,
10 organizations on the NIH list as suppliers having embryonic stem cell lines.
149 key researchers at academic organizations worldwide, and
11 key researchers at commercial organizations.
Because of the early stages of product development, near-term estimates on products currently in development would be pure speculation. The vast majority of products to be discussed have yet to be developed, and we expect any projections made here would be shown to be inaccurate within 5 years.
Stem cell research and the accompanying enabling technologies have virtually
exploded since embryonic stem cells were first isolated in 1998. Many of the enabling
and complementary technologies affecting stem cells are only now catching up to the
rate of research. As such, there is a section on companies that supply the research
companies, including those with cell lines, cell and tissue culture media, and reagents.
The report includes detailed profiles and information on the following:
82 companies involved in the development of stem cell therapeutics, worldwide.
19 laboratories outside the United States with advanced research in the field.
20 detailed profiles on key companies in the industry.
32 suppliers to the Stem Cell Industry of media, sera, and reagents specifically
intended for stem cell research.
10 organizations on the National Institutes of Health list as suppliers of
embryonic stem cell lines.
149 key researchers at academic organizations worldwide.
11 key researchers at commercial organizations.
Because product development is in the early stages, near-term estimates on
products currently in development would be pure speculation. The vast majority of
products discussed in this report have yet to be developed, and we expect that any
projections made here will be shown to be inaccurate within 5 years.
Methodology
The information in this report was taken from primary industry sources;
interviews with company, government, and academic organization officials; and
company submissions such as 10K reports to the Securities and Exchange
Commission, annual reports, biotechnology analyst reports, trade journals, and
medical literature. The author contacted more than 30 companies and individuals
involved in the development of stem cell products. Research began in the spring of
2001 and was completed by the fall of 2001.
Press Release
New Study Identifies Global Stem Cell Industry Leaders
New York, February 13, 2002 /PR Newswire — A new study released today identifies 13 companies as being in the best position to capitalize on the emerging potential of stem cell technologies. The new study from Kalorama Information and available through MarketResearch.com found several companies from the United States, the United Kingdom, and Australia to be well positioned to succeed.
According to the study, Geron Corporation is currently the dominant organization in the field of stem cell therapy for regenerative medicine. However, the status of that dominance may depend on factors such as commercial rights to develop the cell lines produced for the company, competitive factors, the effectiveness of Geron's technology platform, and other environmental factors.
Kalorama’s analysts based their conclusions about the industry leaders on considerations such as progress in stem cell research and development to date, actual revenue as well as revenue potential, product pipeline, intellectual property, key strategic alliances, quality of management and personnel, key acquisitions and agreements, marketing considerations, and manufacturing and regulatory factors.
“Many of the companies active in the field are also active in other therapeutic areas that can generate revenue while stem cell therapies remain in development,” notes Eric Langer, the author of the study. “Given the long development cycle for stem cell products and the associated costs involved, these are the companies that will be most able to realize commercial success with stem cells.”
The study culminated in an exhaustive 400-page report entitled Opportunities in Stem Cell Technology, reviewing all the strategic challenges for this nascent but highly promising field. Technologies, funding (governmental and private), regulation, ethics, licensing and partnership deals, key support technologies, research facilities, and profiles of all the major competitors are included.
Foreword
Objectives
Target Audience
Scope and Content of Report
Methodology
Chapter One: Introduction
What Exactly Is a Stem Cell?
History of the Technology
Corporate Development of Stem Cell Technologies
When Will There Be Payoff?
Stem Cell Background
Stem Cell Terminology
Stem Cell Medical Science
Regenerative Biology
Challenges in Stem Cell Research
Immune Response
Can Stem Cells Be Effective in Regenerating Tissues?
Technical Challenges in Stem Cell Research
Embryonic Stem Cells
Adult Stem Cells
Comparisons of Embryonic and Adult Stem Cells
Similarities: Adult and Embryonic Stem Cells
Differences: Adult and Embryonic Stem Cells
What Is Known About Human Pluripotent Stem Cells?
Adult Stem Cells
What Is Known About Adult Stem Cells?
NIH Funding for Stem Cell Research
Chapter Two: Demographics and Disease Modalities
Potential Disease Modalities
Summary of Important Similarities and Differences Between Adult and Embryonic Stem Cells
Actual and Potential Uses of Human Adult Stem Cells
Potential Uses of Human ES Cells (Plus Certain Nonhematopoietic Uses of Adult Stem Cells)
Using Human Embryonic Stem Cells for Therapeutic Transplants
Special Considerations Regarding the Therapeutic Application of Human ES Cells
Other Potential Uses of Human Embryonic Stem Cells
Conclusions
Chapter Three: Stem Cell Products In Research And Development
The Potential for Stem Cell Products
Areas of Product Development
Neural, Brain, and Spinal Stem Cell Applications
Liver Stem Cell Applications
Pancreas Stem Cell Applications
Cardiac Stem Cell Applications
Renal Stem Cell Applications
Blood Stem Cell Applications
Retinal Stem Cell Applications
Diabetes—Stem Cell Applications
Orthopedics—Stem Cell Applications
Other Stem Cell Applications
Indications
Chapter Four: Stem Cell Companies
Introduction
Companies Involved in Stem Cell Product Development
Source and Type of Stem Cells
Therapeutic Area Targeted by Stem Cell Technology
Safety Issues and Cellular Therapies
Select Stem Cell Company Profiles
Aastrom Biosciences, Inc.
Bioheart, Inc.
BioTransplant, Inc.
Cell Based Delivery, Inc.
Diacrin, Inc.
Geron Corporation, Inc.
ImClone Systems Incorporated
Incara Pharmaceuticals, Inc.
Islet Technology
MorphoGen Pharmaceuticals, Inc.
NeoTherapeutics, Inc.
NeuralStem Biopharmaceuticals, Ltd.
Nexell Therapeutics, Inc.
Osiris Therapeutics, Inc.
ReNeuron, Inc.
SELECT Therapeutics, Inc./Cell Science Therapeutics, Inc.
Stem Cell Pharmaceuticals Inc.
StemCells, Inc.
Titan Pharmaceuticals, Inc.
Chapter Five: Academic Organizations In Stem Cell Research Activities
Introduction
Highlights of Recent Academic Research Activities
Academic and Government Organizations Listed by Area of Activity
Literature Review of Academic and Non-Commercial Organizations Involved with Stem Cells
Hematopoietic Stem Cell Transplantation: mostly stem cell support institutions that published clinical trials or research involving stem cells (2000-2001)
Chapter Six: Stem Cell Research Suppliers and Enabling Technologies
Introduction
Stem Cell Supply Research Activity
Effectiveness of Research Products
Challenges to the Supply Industry
Activities of Suppliers in the Field
Media Development Support for Stem Cell Research
Acquisition Activity
Established Suppliers
Companies on the NIH Stem Cell Registry
Sixty-Four Stem-Cell Lines Eligible for Funding
Concerns about Competence of Approved Cell Lines
Organization Profiles: Organizations with NIH-Listed Stem Cell Lines
Stem Cell Products Background
Bone Marrow Stroma
Mesenchymal Stem Cells
Stem Cell Factor
CFU Assays
Liquid Cell Culture Media
Isolation of Stem Cells
Clonogenic Progenitor Assays, In Vitro Tests
Chapter Seven: Legislative, Social, and Political Issues
Concerns Regarding Origins of Stem Cells
Human Face to the Debates
Political Rulings
Potential for Irresponsible Research
Human Cloning
Scientists Create Human Embryos to Harvest Stem Cells
Risks Associated with Stem Cells in Clinical Applications
Risks Associated with Human Cloning
Private Sector Cloning
Impact of Restrictions on Embryonic Stem Cells
Alternative Sources of Stem Cells
Sources of Human Embryonic Stem Cells
Sources of Other Human Stem Cells
Limitations of Adult Stem Cells
Events in Stem Cell Legislation and Ethics
Public Opinion on Stem Cell Issues
Moral Issues—Opposing Views
Summary of NBAC Review: Ethical Issues Associated with Human Stem Cell
Research
National Institutes of Health Guidelines for Research Using Human Pluripotent Stem Cells
August 2001 Bush Administration Federal Funding Limitations
International Stem Cell Rules and Legislation
European Group on Ethics in Science and New Technologies
Country-Specific Legislation and Guidelines
Chapter Eight: Strategic Issues
The Investment Climate
Funding to Survive Clinical Trials
Licensing Stem Cell Technologies
Technology Partnerships
Stem Cell Licensing Issues
US Regulatory Issues
Federal Agencies Involved in Stem Cell Regulation
FDA Regulatory Overview
Cell and Tissue Regulations
Implementation of the New Regulations
Standard Methods
FDA Market Approvals
Process for Approval of Drugs and Biologics
Process for Approval of Medical Devices
Regulatory Issues Specific to Stem Cell Products
Regulatory Issues in Europe and Japan
Marketing Outside the United States
Reimbursement
Enabling Technologies
Growing or Culturing Stem Cells
Patents and Stem Cells
Appendix A: Stem Cells: A Primer
National Institutes of Health
What is a Stem Cell?
How are pluripotent stem cells derived?
Potential Applications of Pluripotent Stem Cells
Adult Stem Cells
Summary
Appendix B: Stem Cell Researchers and Links
Coalition for the Advancement of Medical Research
Appendix C: Stem Cell Glossary
Key Terms in Stem Cell Technology
General Glossary
List of Exhibits
Table 1-1: Timeline of Human Embryonic Stem Cell Research
Table 2-1: Diseases for Which Unrelated Marrow Donor Transplants Have Been Performed
Table 4-1: Companies, Contact Details, and Descriptions
Table 4-2: Cord blood and Therapeutic Stem Cell Services Companies
Table 5-1. Stem Cells Academic/Government Organizations
Table 6-1: Companies and Research Laboratories with Stem Cell Lines
Table 6-2. Select Organizations Providing Cell Lines
Table 6-3. Cell Culture Systems: Media, Sera and Cell Growth Systems for Stem Cell Reagents: Stem Cell Factors/Cytokines, Antibodies, Conjugates, Growth Factors, Kits, Services Table 7-1: Events in Stem Cell Policy and Ethics
Table 7-2: Results of Poll asking "Do You Support Federal Funding for Stem-Cell Research?"
Table 7-3: Organizations Involved in Bioethics
Table 7-4: Summary of September 1999 NBAC Recommendations on Stem Cell Research
Table B-1: Academic and Government Laboratories Involved in Stem Cell Research Sorted by Organization
Table B-2: Researchers at Commercial Stem Cell Organizations Contributing to 7/01 NIH Report
Table B-3: Stem Cell Web Links
More United States Biopharmaceuticals Reports
The Pharmaceutical Market: USA by
Espicom Healthcare Intelligence
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting ...
Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020) by
IMARC
With sales worth US$ 57 Million in 2010, biosimilars are still far from their billion dollar sales potential that most analysts believe they will generate. ...
Freedonia Focus on Biologics by
Freedonia Focus
This report discusses US biologics demand for the years 2005 and 2010, with forecasts for 2015. Topics covered include product and application segmentation, ...
Biologics by
Freedonia Group Inc
US demand to exceed $100 billion by 2015 Demand for biologics will exceed $100 billion in 2015, experiencing continuing strong growth following a decade of ...
Hot Topics in Multiple Sclerosis: US Prescriber Perception of Biosimilars - Brands to lose over a fifth of patients to copy-cat drugs by
Datamonitor
With healthcare expenditure soaring, the need for more cost-effective treatments is becoming a high priority. Launch of cheaper biosimilars represents a substantial threat to biologic ...
Bisphenol A Industry Outlook in the US to 2015 - Market Size, Company Share, Price Trends, Capacity Forecasts of All Active and Planned Plants by
GlobalData
Bisphenol A Industry Outlook in the US to 2015 - Market Size, Company Share, Price Trends, Capacity Forecasts of All Active and Planned Plants Summary GlobalData’s report, ...
Industrial Designers in the US - Industry Market Research Report by
IBISWorld
Industrial Designers in the US A premium on creativity : As technology becomes more prevalent in everyday life and products become more standardized, companies require something beyond ...
2012 U.S. Drinking Places & Bars Industry-Industry & Market Report by
Barnes Reports
The Drinking Places & Bars Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features ...
2012 U.S. Direct Mail Advertising Industry-Industry & Market Report by
Barnes Reports
The Direct Mail Advertising Industry-Industry & Market report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features ...
2012 U.S. Department Stores Industry-Industry & Market Report by
Barnes Reports
The Department Stores Industry-Industry & Market report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2012 ...
(0 items)
